百济神州业绩快报：2025年度归母净利润14.22亿元，同比扭亏

Core Insights - The company reported a total revenue of 38.205 billion yuan for the fiscal year 2025, representing a year-on-year growth of 40.40% [1] - The net profit attributable to shareholders was 1.422 billion yuan, a significant recovery from a net loss of 4.978 billion yuan in the same period last year [1] - The basic earnings per share stood at 1 yuan [1] Revenue Breakdown - Product revenue reached 37.770 billion yuan, up from 26.994 billion yuan in the previous year [1] - The growth in product revenue was primarily driven by sales of Baiyueze® (Zebutinib), licensed products from Amgen, and Baizean® (Tislelizumab) [1]